Diabetes stakeholders oppose competitive bidding
This article was originally published in The Gray Sheet
Executive Summary
The National Association of Chain Drug Stores maintains that inclusion of diabetes products in the impending DMEPOS competitive bidding program may prevent patient access to the most appropriate equipment and supplies. NACDS cites a report by Health Policy R&D, indicating that failing to control glucose levels is significantly more costly than the costs of glucose meters and related supplies. The request to exclude diabetes products reiterates pleas made by industry stakeholders during a Program Advisory & Oversight Committee meeting in Sept. 2005 (1"The Gray Sheet" Oct. 3, 2005, p. 15). Under Sec. 302 of the Medicare Modernization Act, durable medical equipment, prosthetics, orthotics and supplies will be subject to competitive bidding in 2007 (2"The Gray Sheet" Jan. 23, 2006, p. 16)...
You may also be interested in...
DME Competitive Bidding Program Not Likely To Begin Until After Jan. 2007
CMS' proposed rule on the competitive bidding program for durable medical equipment is in the final stages of review and should be released soon, according to Center for Medicare Management Director Herb Kuhn
Diabetes Products Should Be Exempt From Competitive Bidding – Panel
Supplier and manufacturer stakeholders are urging CMS to exclude blood glucose testing products from the impending DMEPOS competitive bidding program
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.